Intended for healthcare professionals


FDA recalls ranitidine medicines over potential cancer causing impurity

BMJ 2019; 367 doi: (Published 02 October 2019) Cite this as: BMJ 2019;367:l5832
  1. Elisabeth Mahase
  1. The BMJ

The US Food and Drug Administration has asked doctors and patients to return certain batches of over-the-counter ranitidine tablets (75 mg and 150 mg), after low levels of the probable human carcinogen N-nitrosodimethylamine (NDMA) were detected.1

The FDA released updates to the public and doctors explaining that some ranitidine medicines might contain low levels of NDMA and asked for any tablets labelled by Walgreens, Walmart, or Rite-Aid …

View Full Text

Log in

Log in through your institution


* For online subscription